1877.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 04:08):

Stats
Today's Volume	2.28M
Average Volume	1.24M
Market Cap	23.78B
EPS	HKD-0.237 ( 2019-06-29 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-4.28
ATR14	HKD0.0300 (0.28%)

Volume Correlation

Long: -0.09 (neutral)

Short: 0.85 (strong)

Signal:(52.263) Same movement expected

JUNSHI BIO Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

JUNSHI BIO Correlation - Currency/Commodity

-0.46
( neutral )

-0.41
( neutral )

0.00
( neutral )

-0.38
( neutral )

0.00
( neutral )

0.06
( neutral )

JUNSHI BIO Financials

Annual	2023
Revenue:	HKD1.50B
Gross Profit:	HKD868.16M (57.78 %)
EPS:	HKD-2.32

FY	2023
Revenue:	HKD1.50B
Gross Profit:	HKD868.16M (57.78 %)
EPS:	HKD-2.32

FY	2022
Revenue:	HKD1.45B
Gross Profit:	HKD927.21M (63.79 %)
EPS:	HKD-2.81

FY	2021
Revenue:	HKD4.02B
Gross Profit:	HKD2.77B (68.74 %)
EPS:	HKD-0.800

Financial Reports:

No articles found.

JUNSHI BIO

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.